Log In
BCIQ
Print this Print this
 

ChondroCelect (TGX001)

  Manage Alerts
Collapse Summary General Information
Company TiGenix N.V.
DescriptionAn implantation suspension of characterized viable autologous cartilage cells
Molecular Target Not applicable
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentMarketed
Standard IndicationCartilage repair
Indication DetailsRepair single symptomatic cartilage defects of the femoral condyle of the knee; Treat cartilage defects of the knee
Regulatory Designation
PartnerSwedish Orphan Biovitrum AB

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$7.9M

$5.8M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/24/2014

$7.9M

$5.8M

0

Get a free BioCentury trial today